Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
47.37
-0.26 (-0.55%)
Feb 21, 2025, 4:00 PM EST - Market closed
Merus Revenue
Merus had revenue of $11.77M in the quarter ending September 30, 2024, with 6.70% growth. This brings the company's revenue in the last twelve months to $35.93M, down -21.33% year-over-year. In the year 2023, Merus had annual revenue of $43.95M with 5.68% growth.
Revenue (ttm)
$35.93M
Revenue Growth
-21.33%
P/S Ratio
81.10
Revenue / Employee
$156,908
Employees
229
Market Cap
3.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
| Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
| Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
| Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
| Dec 31, 2019 | 31.13M | -7.25M | -18.88% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
MRUS News
- 4 days ago - Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma - GlobeNewsWire
- 9 days ago - Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - GlobeNewsWire
- 17 days ago - New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewsWire
- 4 weeks ago - Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff - Seeking Alpha
- 5 weeks ago - Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - GlobeNewsWire
- 2 months ago - Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - GlobeNewsWire
- 2 months ago - Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC - GlobeNewsWire
- 2 months ago - Merus Scores Its First FDA Approval For Lung Cancer Drug - Benzinga